Tag: alto
Endologix announces 150th patient enrolled in JAGUAR randomised controlled trial
Endologix recently announced the completion of the 150th case in the JAGUAR study.
This randomised controlled trial is evaluating Endologix’s Alto abdominal stent graft...
Disruptive technology and high-quality clinical evidence: An Endologix transformation
NOTE: This video is ONLY available to watch in selected countries and geographies
Endologix president and CEO, Matt Thompson (Irvine, USA), discusses how the...
Endologix initiates randomised study of Alto abdominal stent graft system
Endologix today announced that the first patient has been enrolled in the company’s JAGUAR study to compare outcomes for the Alto abdominal stent graft...
Endologix announces launch of Alto abdominal stent graft system in Canada...
Endologix today announced the first implant of its Alto abdominal stent graft in Canada following recent approval from Health Canada. Alto was also recently...
Endologix launches Alto abdominal stent graft system in Europe
Endologix today announced the first implant of its Alto abdominal stent graft, commencing the European commercial release of the recently CE mark approved endograft.
“We...
Endologix announces first commercial implant of Alto abdominal stent graft system...
Endologix has announced the first implant of its recently approved Alto endograft outside of the USA, completed by Andrew Holden and Andrew Hill of...
Endologix receives CE mark for Alto abdominal stent graft system
Endologix recently announced that it has received a CE mark for the Alto abdominal stent graft system.
“We are very excited to receive a CE...
Endologix announces first commercial implant and US release of Alto abdominal...
Endologix has announced the first commercial implant and the US commercial release of its recently US Food and Drug Administration (FDA)-approved Alto endograft for...
Endologix receives FDA approval for Alto abdominal stent graft system
Endologix recently announced that it has received approval from the US Food and Drug Administration (FDA) for the Alto abdominal stent graft system (Alto).
The...
Cagent Vascular completes enrolment of PRELUDE study using Serranator Alto device
Cagent Vascular has announced the completion of enrolment in the first-in-human PRELUDE study. The purpose of this prospective, single-arm, multicentre feasibility study is to...
